Printer Friendly

CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH

 CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
 WEST CHESTER, Pa., July 17 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) and their collaborators reported progress in the identification of the role of certain proteases (enzymes) in the beta amyloid plaque formation characteristic of Alzheimer's disease.
 Speaking at the Third International Conference on Alzheimer's Disease and Related Disorders, in Padova, Italy, Dr. Robert Siman, director of biochemistry for Cephalon, reported on two proteases (the multicatalytic protease and cathepsin G) which in preclinical studies by Cephalon have been shown to possess the cleavage specificity to liberate the beta amyloid peptide. In addition, Cephalon's collaborator Dr. Carmella Abraham, Boston University, reported on the potential role of two additional proteases, calcium activated serine and metal dependent cystine in the processing of beta amyloid.
 "The research presented at this symposium focused on our protease discovery effort and elucidated the potential role of some key human proteases in the


generation of beta amyloid," indicated Dr. Frank Baldino, Jr., president and CEO of Cephalon, Inc. "Using our synthetic chemistry approach, Cephalon has begun making non-peptide inhibitors of the proteases believed to be involved in plaque formation."
 Alzheimer's disease is an intractable, chronic, and progressively incapacitating disease characterized by the presence of neuritic plaques in the brain and the depth of several types of neurons, including cortical and cholinergic cells. The deposition of amyloid plaques in Alzheimer's disease is a result of the improper processing of the beta amyloid protein. Identification of the role of proteases in the processing of beta amyloid is a key step in the development of inhibitors which may represent therapeutic targets for the disease. It is an age dependent disorder which afflicts as many as four million individuals in the United States.
 In May 1990, Cephalon and Schering-Plough Corporation entered into a licensing agreement to develop new drugs for the treatment of Alzheimer's disease and related disorders. Under the collaboration, Cephalon and Schering-Plough are conducting two research programs to treat Alzheimer's disease. One focuses on developing protease inhibitors to prevent the deposition of amyloid. The second seeks to increase the endogenous production of naturally occurring growth factor proteins in the brain, using small neurotrophic factor-enhancing molecules (NEMs).
 Cephalon, Inc. focuses on the development of products to treat neurodegenerative diseases. These diseases are characterized by the death of neurons, the specialized conducting cells of the nervous system. The company has concentrated its research programs on the prevention of neuronal death in several disorders, including ALS, Alzheimer's disease, head and spinal cord injuries, stroke, peripheral neuropathy and retinopathy. There is currently no effective treatment for these conditions which, in the aggregate, afflict over six million people in the U.S.
 -0- 7/17/92
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-545-1919, for Cephalon/
 (CEPH) CO: Cephalon, Inc.; Schering-Plough Corporation ST: Pennsylvania IN: MTC SU: PDT


TS-LD -- NY003 -- 0087 07/17/92 08:46 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 17, 1992
Words:482
Previous Article:INDIANA FEDERAL DECLARES QUARTERLY DIVIDEND
Next Article:BROADWAY & BROADWAY SOUTHWEST LAUNCH JERRY GARCIA'S NEW TIE COLLECTION
Topics:


Related Articles
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON, INC. RECEIVES SBIR GRANT FROM THE NIH TO RESEARCH NOVEL THERAPEUTICS FOR BRAIN AND SPINAL CORD NERVE DAMAGE AND DEGENERATION
CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CEPHALON PRESENTS SIGNIFICANT DISCOVERY IN ALZHEIMER'S DISEASE PROGRAM
CEPHALON APPOINTS SENIOR MEDICAL DIRECTOR
CEPHALON AND CHIRON REPORT SUCCESSFUL SECOND STUDY OF MYOTROPHIN; EUROPEAN DATA CONFIRM BENEFICIAL EFFECTS OF MYOTROPHIN IN ALS
CEPHALON AND SCHERING-PLOUGH RENEW ALZHEIMER'S DISEASE RESEARCH COLLABORATION
CEPHALON AND CHIRON TO HAVE ADDITIONAL DISCUSSIONS WITH FDA ABOUT MYOTROPHIN TREATMENT IND
Cephalon and TAP Launch Phase I Cancer Study
Cephalon and Schering-Plough Conclude Alzheimer's Disease Research Collaboration

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters